Viridian Therapeutics Inc
NASDAQ:VRDN

Watchlist Manager
Viridian Therapeutics Inc Logo
Viridian Therapeutics Inc
NASDAQ:VRDN
Watchlist
Price: 20.2 USD 2.96% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Viridian Therapeutics Inc?
Write Note

Viridian Therapeutics Inc
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Viridian Therapeutics Inc
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Viridian Therapeutics Inc
NASDAQ:VRDN
Other Current Liabilities
$288k
CAGR 3-Years
-1%
CAGR 5-Years
N/A
CAGR 10-Years
-14%
Abbvie Inc
NYSE:ABBV
Other Current Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Other Current Liabilities
$11.7B
CAGR 3-Years
197%
CAGR 5-Years
551%
CAGR 10-Years
53%
Amgen Inc
NASDAQ:AMGN
Other Current Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Current Liabilities
$357.6m
CAGR 3-Years
21%
CAGR 5-Years
36%
CAGR 10-Years
27%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Current Liabilities
$627.2m
CAGR 3-Years
7%
CAGR 5-Years
1%
CAGR 10-Years
24%
No Stocks Found

Viridian Therapeutics Inc
Glance View

Market Cap
1.6B USD
Industry
Biotechnology

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 86 full-time employees. The company went IPO on 2014-06-18. The firm is engaged in developing three product candidates, VRDN-001, VRDN-002, and VRDN-003, that is developed for intravenous (IV) or subcutaneous administration to treat patients who suffer from thyroid eye disease (TED). Its lead product candidate, VRDN-001, is a differentiated humanized monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the TED. The company has initiated a Phase I/II clinical trial of VRDN-001. Its second product candidate, VRDN-002, is a distinct IGF-1R antibody that incorporates half-life extension technology, and is designed to support administration as a convenient, low volume, subcutaneous injection to treat patients who suffer from TED. VRDN-003 is an anti-IGF-1R monoclonal antibody with the same amino acid sequence as VRDN-001.

VRDN Intrinsic Value
7.68 USD
Overvaluation 62%
Intrinsic Value
Price

See Also

What is Viridian Therapeutics Inc's Other Current Liabilities?
Other Current Liabilities
288k USD

Based on the financial report for Sep 30, 2024, Viridian Therapeutics Inc's Other Current Liabilities amounts to 288k USD.

What is Viridian Therapeutics Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
-14%

Over the last year, the Other Current Liabilities growth was -4%. The average annual Other Current Liabilities growth rates for Viridian Therapeutics Inc have been -1% over the past three years , and -14% over the past ten years .

Back to Top